(Q33872072)

29 July 2017

1 reference

title

Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques (English)

1 reference

29 July 2017

E S Surrey

1

1 reference

29 July 2017

W B Schoolcraft

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

29 July 2017

published in

Fertility and Sterility

1 reference

29 July 2017

volume

73

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

667-676

1 reference

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Serum levels of luteinizing and follicle-stimulating hormones in normal and poor-responding patients undergoing ovarian stimulation with urofollitropin after pituitary downregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Poor responders to ovulation induction: is proceeding to in-vitro fertilization worthwhile?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Limited success using the "flare" protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Comparison of growth hormone responses to growth hormone-releasing factor and clonidine in women with normal or poor ovarian response to gonadotropin stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

IVF: induction of ovulation in poor responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The value of increasing the dose of human menopausal gonadotropins in women who initially demonstrate a poor response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Gonadotropins and estradiol stimulate immunoreactive insulin-like growth factor-I production by porcine granulosa cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth factor I in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Growth hormone enhances follicle-stimulating hormone-induced differentiation of cultured rat granulosa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Growth hormone co-treatment for ovulation induction may enhance conception in the co-treatment and succeeding cycles, in clonidine negative but not clonidine positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The value of human growth hormone as an adjuvant for ovarian stimulation in a human in vitro fertilization program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Absence of effect of adjuvant growth hormone therapy on follicular responses to exogenous gonadotropins in women: normal and poor responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Another look at co-treatment with growth hormone and human menopausal gonadotrophins in poor ovarian responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Combined treatment with gonadotrophin releasing hormone agonist and gonadotrophins in poor responders to hyperstimulation for in vitro fertilization (IVF): clinical and endocrine results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Short-term use of gonadotropin-releasing hormone agonist (leuprolide) for in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Ovarian suppression with leuprolide acetate: comparison of luteal, follicular, and flare-up administration in controlled ovarian hyperstimulation for oocyte retrieval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Comparison of a blocking vs. a flare-up protocol in poor responders with a normal and abnormal clomiphene citrate challenge test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The ovarian androgen producing cells: a review of structure/function relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The Microenvironment of the Human Antral Follicle: Interrelationships among the Steroid Levels in Antral Fluid, the Population of Granulosa Cells, and the Status of the Oocyte in Vivo and in Vitro *

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization--a prospective randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Gonadotropin suppression with oral contraceptives before in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The morphogenic/cytotoxic and prostaglandin-stimulating activities of interleukin-1 beta in the rat ovary are nitric oxide independent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Gonadotropin responsiveness to ultralow-dose leuprolide acetate administration in baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: evidence for a second flare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Prognostic assessment of ovarian reserve.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Prognostic value of day 3 estradiol on in vitro fertilization outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

The Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Use of the antral follicle count to predict the outcome of assisted reproductive technologies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Direct effect of gonadotropin-releasing hormone agonists on the rabbit ovarian follicle

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2899%2900630-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0015-0282(99)00630-5

1 reference

29 July 2017

1 reference